Idaho is still seeking a way to get its state's health insurance plans approved by CMS; a new poll finds that support for action on drug pricing dips when potential ramifications are weighed; senators seek information on hospitals' use of 340B drug discounts.
Idaho insurance head Dean Cameron and Sen. Jim Risch, R-Idaho, met with CMS chief Seema Verma in Washington this week to see if there is still a way around the state’s controversial plan to skirt Affordable Care Act (ACA) rules, The Hill reported. The Trump administration has blocked the plan, saying that it contained measures that violated the ACA, such as allowing people with pre-existing conditions to be charged more. Cameron said that perhaps a discount might be given to healthy people instead.
A POLITICO—Harvard T.H. Chan School of Public Health poll finds bipartisan support for the idea of drastic government action on drug prices. Nine out of 10 favor giving Medicare the power to negotiate directly with pharmaceutical manufacturers, but that support falters when Americans face possible negative trade-offs, Politico reported. Support fell to 42% when respondents weighed the risk that some drug companies might respond by halting the sale of certain drugs to seniors. And although 80% favored limiting the price of drugs sold to state health programs, only 38% still liked the idea if it meant less research and development.
Senators moved closer to joining the House of Representatives to push hospitals to report how they use 340B drug discounts, Modern Healthcare reported. Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, R-Tennessee, said he wants to know where hospitals and clinics are applying the drug discounts, how much of the discounts go to patients, and which kinds of programs the providers are funding for patients with the money that isn't directly passed on. It’s the first time senators have gotten involved in the lobbying dispute between the pharmaceutical industry and hospitals.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More